June 14, 2018 10:11 AM EDT

Researchers outline another big disease target for Novartis’ canakinumab as drug slashes rate of gout flares

John Carroll

Editor & Founder

We’ve already seen Novartis’ outline of positive data underscoring canakinumab’s ability to reduce risks for cardio patients by tamping down on the interleukin-1β pathway. Now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Researchers outline another big disease target for Novartis’ canakinumab as drug slashes rate of gout flares

John Carroll

Editor & Founder

Sign up to read this article for free.

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Sana narrows focus again to zero in on diabetes and autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Re­searchers out­line an­oth­er big dis­ease tar­get for No­var­tis’ canakinum­ab as drug slash­es rate of gout flares

John Carroll

Editor & Founder

Sign up to read this article for free.

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Researchers outline another big disease target for Novartis’ canakinumab as drug slashes rate of gout flares

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Sana narrows focus again to zero in on diabetes and autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks